We are live on
!
Find out more
Theravance Biopharma
TBPH
TBPH
173 hedge funds and large institutions have $813M invested in Theravance Biopharma in 2026 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 60 increasing their positions, 46 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
30% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 46
21% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 34
2% more funds holding
Funds holding: 169 → 173 (+4)
0.58% less ownership
Funds ownership: 97.87% → 97.29% (-0.58%)
12% less capital invested
Capital invested by funds: $927M → $813M (-$114M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
93% less call options, than puts
Call options by funds: $847K | Put options by funds: $11.6M
Holders
173
Holders Change
+4
Holders Change %
+2.37%
% of All Funds
2.13%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.05%
New
41
Increased
60
Reduced
46
Closed
34
Calls
$847K
Puts
$11.6M
Net Calls
-$10.7M
Net Calls Change
-$13.3M
Top Buyers
| 1 |
Two Sigma Investments
New York
|
+$12.8M |
| 2 |
NM
Newtyn Management
New York
|
+$9.58M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.66M |
| 4 |
6CM
683 Capital Management
New York
|
+$4.42M |
| 5 |
BlackRock
New York
|
+$4.35M |
Top Sellers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$11.2M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$6.57M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$5.77M |
| 4 |
D.E. Shaw & Co
New York
|
-$5.41M |
| 5 |
Morgan Stanley
New York
|
-$5.18M |
